Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Recently identified and potential targets for colon cancer treatment.

Lea MA.

Future Oncol. 2010 Jun;6(6):993-1002. doi: 10.2217/fon.10.53. Review.

PMID:
20528236
2.

Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism.

Priego S, Feddi F, Ferrer P, Mena S, Benlloch M, Ortega A, Carretero J, Obrador E, Asensi M, Estrela JM.

Mol Cancer Ther. 2008 Oct;7(10):3330-42. doi: 10.1158/1535-7163.MCT-08-0363.

3.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. Review.

PMID:
17944568
4.

The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.

Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S.

Clin Cancer Res. 2010 Nov 15;16(22):5436-46. doi: 10.1158/1078-0432.CCR-10-2054. Epub 2010 Oct 13.

5.

Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.

Freeman JW, Wang Y, Giles FJ.

Cancer Biol Ther. 2009 Jul;8(14):1340-2. Epub 2009 Jul 17. No abstract available.

PMID:
19440037
6.

Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.

Weirauch U, Beckmann N, Thomas M, Grünweller A, Huber K, Bracher F, Hartmann RK, Aigner A.

Neoplasia. 2013 Jul;15(7):783-94.

7.

DNA demethylating agents and epigenetic therapy of cancer.

Mani S, Herceg Z.

Adv Genet. 2010;70:327-40. doi: 10.1016/B978-0-12-380866-0.60012-5. Review.

PMID:
20920754
8.

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen TF, Pfeiffer P, Brünner N, Ørntoft TF, Andersen CL.

Mol Oncol. 2013 Jun;7(3):637-46. doi: 10.1016/j.molonc.2013.02.016. Epub 2013 Feb 28.

9.

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.

Cang S, Ma Y, Liu D.

J Hematol Oncol. 2009 Jun 1;2:22. doi: 10.1186/1756-8722-2-22. Review.

10.

The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer.

Kong Y, Bai PS, Sun H, Nan KJ, Chen NZ, Qi XG.

Int J Biochem Cell Biol. 2012 Dec;44(12):2321-32. doi: 10.1016/j.biocel.2012.08.006. Epub 2012 Aug 10.

PMID:
22903020
11.

MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.

Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A.

Cancer Res. 2011 Aug 1;71(15):5214-24. doi: 10.1158/0008-5472.CAN-10-4645. Epub 2011 Jun 20.

12.

Targeting c-Myb expression in human disease.

Ramsay RG, Barton AL, Gonda TJ.

Expert Opin Ther Targets. 2003 Apr;7(2):235-48. Review.

PMID:
12667100
13.

miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.

Chai H, Liu M, Tian R, Li X, Tang H.

Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):217-25. doi: 10.1093/abbs/gmq125. Epub 2011 Jan 17.

PMID:
21242194
14.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

15.

The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.

Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM.

Cell Death Dis. 2013 Sep 19;4:e810. doi: 10.1038/cddis.2013.330.

16.

Epigenetic regulation of gene expression as an anticancer drug target.

Ferguson LR, Tatham AL, Lin Z, Denny WA.

Curr Cancer Drug Targets. 2011 Feb;11(2):199-212.

PMID:
21158714
17.

Targeting aspartate aminotransferase in breast cancer.

Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J.

Breast Cancer Res. 2008;10(5):R84. doi: 10.1186/bcr2154. Epub 2008 Oct 15.

18.

Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.

Liu T, Liu PY, Tee AE, Haber M, Norris MD, Gleave ME, Marshall GM.

Eur J Cancer. 2009 Jul;45(10):1846-54. doi: 10.1016/j.ejca.2009.03.002. Epub 2009 Apr 1.

PMID:
19342222
19.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.

J Cell Physiol. 2007 Aug;212(2):330-44. Review.

PMID:
17458893
20.

Epigenetic opportunities and challenges in cancer.

Best JD, Carey N.

Drug Discov Today. 2010 Jan;15(1-2):65-70. doi: 10.1016/j.drudis.2009.10.010. Epub 2009 Nov 6. Review.

PMID:
19897050

Supplemental Content

Support Center